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1. Introduction 
Human prolactin is a single-chain polypeptide hormone. It has a molecular weight of 
approximately 22,500 Da (figure 1). It takes part in lactation through physiological and 
biochemical events.  
Its polypeptide chain consists of 198-200 amino acid remainders which complete sequence is 
unknown. Over 80% of the first 50 amino acids are identical or equivalent to the bovine 
prolactin. 
The prolactin molecule is arranged in a single chain of amino acids with three intra 
molecular disulfide bonded between six cysteine residues (Cys4-Cys11, Cys58-Cys174, 
Cys191-Cys199 in humans). The sequence homology can vary from the striking 97% among 
primates to as low as 56% in rodents (1) 
The sequence of the first 23 amino acid remainders corresponding to the N-terminal extreme 
NH2-leu-pro-ile-cys-pro-gly-ala-ala-arg-cys-gln-val-thr-leu-arg-asp-leu-phe-asp-arg-ala-val 
It’s secreted by the anterior part of the hypophysis, the adenohypophysis (figure 2) that 
stimulates the milk production in the mammary glands and the progesterone synthesis in 
the corpus luteum. 
Although the major form of prolactin found in the pituitary gland is 23 kDa, variants of 
prolactin have been characterized in many mammals, including humans. Prolactin variants 
can be results of alternative splicing of the primary transcript, proteolytic cleavage and other 
posttranslational modifications of the amino acid chain (1) 
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Source: Originally from en.wikipedia; description page is/was here. 
Author: Original uploader was BorisTM at en.wikipedia 
Permission (Reusing this file): Released into the public domain (by the author); PDB 
Figure 1. Prolactin´s structure 
 
This image is propriety of our laboratory and created by us. 
Figure 2. Prolactin’s secretion. 
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It was discovered in 1928 in a cow´s hypophysis and it is phylogenetically considerated  as 
the oldest known hormone in the animal kingdom. It has been detected in insects, 
amphibian, fish and mammals. Its luteotrophic activity was not discovered until 1945 (2-4). 
Its isolation was difficult due to its structure, which is similar (in a 16%) to the growth 
hormone (GH) structure. Both are located in the hypophysis, but the GH is present in higher 
concentration. Its existence was demonstrated through a trial series performed between 1965 
and 1971, it was discovered, as well, the way its secretion is performed, where some 
physiological factors are positive and negative hypothalamic neurohormonal compounds  
(5-6). 
Studies on the secondary structure of prolactin have shown that 50% of the amino acid chain 
is arranged in α-helices, while the rest of it forms loops. Although it was predicted earlier, 
there are still no direct data about the three-dimensional structure of prolactin. The tertiary 
structure of prolactin was predicted by homology modeling approach, based on the 
structural similarities between prolactin and other helix bundle proteins, especially growth 
hormone. 
According to the current three-dimensional model, prolactin contains four long α-helices 
arranged in antiparallel fashion (1).  
It shows a synergic effect with the following hormones: estrogens, progesterone and GH. 
 
This image is propriety of our laboratory and created by us. The data was taken from Benavides IZ, Castillo AP, 
Montemayor I, DeEstrada R,Onatra W, Posso H. Biorritmo de prolactina en mujeres de edad reproductiva 
vs.Perimenopáusicas.Rev Coloma Menop.2003;9:153–8.[16 Sep 2009].  
Figure 3. Prolactin’s circadian rhythm 
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The nipple suction during breastfeeding favors a bigger amount of hormone synthesis. 
Besides, it’s one of the few physiological systems that have positive feedback, so the 
presence of prolactin in the organism favors this peptide production. 
Nipple and areola´s terminal nerves are stimulated when suction occurs. This stimulus 
travels via afferent nerve pathways to the hypothalamus, proving the prolactin release, by 
inhibition of the release of dopamine. (5-9) 
Prolactin levels during pregnancy rise from its normal value up to 200 or 400 ng/ml. This 
increase starts around the 8th week in a simultaneous way with the estrogen increasing. The 
rising in prolactin secretion is due to the suppression that estrogens provoke over dopamine 
and the direct stimulation of the transcription of the prolactin gene in the hypophysis. (8) 
Prolactin shows a circadian and pulsatile rhythm (figure 3) that starts raising 90 minutes 
after sleep beginning, with maximum peaks at 4-5 hours and it can stay high two hours after 
waking up (7-9). 
It is known that its discharges are 20-30 minutes intervals and the mean life is 20-30 minutes 
(7-11). 
The main circulating form is the monomeric prolactin (little prolactin) or native prolactin 
which is a non-glycosylated monomer that makes up the 80-90% of the total amount of 
prolactin in a normal individual. 
Another circulating form in the big prolactin (big PRL) which consist in glycosylated dimers 
or trimers of 40.000-50000 daltons molecular weight, which is supposed to be a deposit form 
which is rarely detected in serum and which biological activity is nearly non-existent. 
However, it is detected in hyperprolactinemia without any pathological clinical signs. 
Finally, big-big prolactin or macroprolactin wich is a dimer form of the big-PRL joined to 
IgG immunoglobulin with a molecular weight over 100000 daltons and without any 
biological activity (10-12). 
2. Effects 
The prolactin´s main function in women is to stimulate and maintain the puerperal 
breastfeeding, direct action over acidophilic cells known as lactotrophs cells of the 
mammary glands (6, 13). Estrogens, GH, corticoids, placental lactogenic hormones and 
prolactin are needed to increase the ductal system. Estrogens, progesterone and prolactin 
are needed to develop the lobuloalveolar system, so levels of these hormones should be 
considered in pathological states as fibrocystic mastopathy, mastodynia (breast pain), 
mammary carcinoma, etc. 
Among its effects over the mammary alveolar cells there is an increase of the lactose 
synthesis and a higher production of lactose proteins as casein and lactalbumin. 
It is related with the reproductive cycle, the pregnancy maintenance and the fetal growth, 
through an effect over the mother metabolism acting over different effector organs to 
facilitate its functions through synergy or inhibition of other hormones.  
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It shows a synergism with the gonadal steroid hormones  in the continuance of the corpus 
luteum and progesterone production, with action in the reproductive processes, according 
to some researches that revealed the presence of specific prolactin receptors in the 
mammal´s ovaries, transferring part of the progesterone function which, among other 
functions, stimulates the formation of membrane receptors for the follicle stimulating 
hormone (FSH) and the luteinizing hormone (LH) for the follicle growth and the estradiol 
synthesis. It was found, in the little antral follicles, a prolactin concentration 6 times higher 
than in circulation, when the follicle is 6-8 mm of diameter the levels drop, getting close to 
the basal blood levels near the ovulation (3, 4, 12, 14). 
Some secondary functions or less powerful have been reported, being related to 
androgenesis that takes part in the suprarenal cortex reticular area, where some specific 
receptors for prolactin have been found, the joint with those receptors stimulates the 
secretion of dehydroepiandrosterone and its sulfate.  
Prolactin has also an inhibitory effect over the gonadotropin secretion, so its hypersecretion 
can cause oligomenorrhea or amenorrhea in women (3,4, 14). 
In men, the prolactin behavior can affect the adrenal function, the electrolytic balance, 
gynecomastia, galactorrhea sometimes, libido decreasing and sexual impotence and some 
other actions in prostate, seminal vesicles and testicles (15-17). 
Prolactin serum levels have daily and circadian variations, its secretion is pulsatile, as 
described by Sassin et al, measuring blood levels every 20 minutes with raises up to 50% 
(13). 
It shows a circadian rhythm with increases or secretory peaks during the sleep, started 
between 10 minutes and one hour after sleep beginning and reaching the highest values 
mainly in the deepest stages. These values do not go down in the next two hours after 
waking up and decrease slowly by the end of the afternoon, without any tendency to be 
repeated in the same individual in the days after, once in circulation prolactin mean life is 
estimated around 14 minutes. 
It seems that variation during time and sleep are due to the hypothalamus dopaminergic 
stimulus modifications, the circadian fluctuation is not affected by the use of oral 
contraceptives (10-15). 
3. Limits of reference 
In blood, prolactin can be found from the 16th week of fetal life, increasing its levels due to 
active secretion, as in birth it shows higher amounts to the ones recorded in the mother. 
The normal described limits (figure 4 y 5) for healthy population are the following: 
 Men: 2 - 18 ng/mL 
 Non-pregnant women: 1 - 46 ng/mL 
 Pregnant women: 35 - 600 ng/mL 
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This image is propriety of our laboratory and created by us.The data was taken from  Fuchs, F. y Koppler A. 
Endocrinología de la Gestación. 1982. Segunda edición. Salvat Editores,S.A. Capítulo 12. Pag. 249-72  
Figure 4. Prolactin’s limits of reference (I) 
 
This image is propriety of our laboratory and created by us. The data was taken from Tyson JE, Hwang P, Guyda H, 
Friesen Hg. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972;113:14-20. 
Figure 5. Prolactin’s limits of reference (II) 
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The limits of reference change according to the studied population showing very 
pronounced individual variations, even in age and sex groups. 
In fertile women the levels show a light elevation during ovulation and the luteinic phase, 
concerning to the follicular phase, corresponding to the endogenous estrogens liberated by 
the ovaries, which reduce the prolactin inhibitory factor in the hypothalamus increasing the 
amount of lactotroph cells as demonstrated in rats by stimulation although that effect 
depends on the dose and duration of the application, but it used to be shown by 24 hours (3, 
12-15). 
In postmenopausal woman and elderly men, levels go down, it is not clear if it is due 
pituitary deficiency or gonadal insufficiency, showing some role in gonadal function and 
aging. 
The presence of different nonspecific stimulus, as the coitus, exercises, stress situations as 
surgery, insulin hypoglycemia course….can cause variations in prolactin secretion, some of 
the can have an adaptive nature, as them one occurred in hypoglycemia (12). 
Because of what we mentioned previously, it is recommended to take from 2 to 3 samples to 
determine the prolactin level after 9 am to avoid late effects at night and hypoglycemia. 
4. Hyperprolactinemia 
As it has been described before, prolactin is secreted by lactotroph cells from the anterior 
hypophysis and it is subjected to the dopamine inhibitory effect in the hypothalamus. Any 
cause which interferes in its synthesis, the transport to the pituitary gland or the action over 
the dopamine receptors can produce hyperprolactinemia (Table 1). 
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Antipsychotics: phenothiazine (chlorpromazine, perphenazine, fluphenazine, thorazine, 
promazine, fluoperazine, trifluoperazine, etc.), haloperidol, butyrophenone. 
Other dopaminergic blockers: metoclopramide, sulpiride, domperidone, cisperidone, 
cisapride. 
Antidepressant: monoamine oxidase inhibitors (imipramine), amoxapine, Tryciclic 
antidepressants. 




Opiates: cocaine, morphine, heroine. 
Benzodiazepine 
Cimetidine (iv) 




Adrenergic receptor antagonists (medroxalol) 
Neurogenic causes
Thoracic wall lesions 




Chronic renal insufficiency 
Liver cirrhosis 
Suprarenal insufficiency 
Polycystic ovary syndrome 
Convulsions 
Idiopathic macroprolactinemia 
GABA: Gamma-aminobutyric acid 
HRT: Homone replacement therapy 
Iv: intra-venous 
Table 1. Hyperprolactinemia causes 
The most important cause of hyperprolactinemia is the secretory pituitary adenoma. 
Nevertheless, the most common cause are drugs and, when it is possible, the serum 
prolactin determination should be done once those are suspended. 
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5. Physiological causes 
1. Pregnancy 
Serum prolactin rises in a progressive way during gestation, but in a variable manner (18-
19). At the end, the mean value is around 200 ng/ml but the range is 35-600. 
Around the 6th week from the labor the normoprolactinemia is restored. Although the 
prolactin concentration is high before the labor, the milk secretion only takes place after it, 
because the high presence of estrogens and progesterone in pregnant women has an 
inhibitory effect over the milk secretion. When these hormones levels drop after the labor, 
lactation is produced. 
During gestation the prolactin levels in the amniotic liquid can reach the 1000 ng/ml, higher 
concentration that any other organic fluid, this happens around the 15th and the 20th week of 
gestation and it drops slowly until the end of the pregnancy to 450 ng/ml. It is supposed to 
be produced by the fetal and the mother´s hypophysis, with a possible function of fetal 
osmoregulation to survive in the intrauterine liquid environment, helping and contributing 
to the pulmonary maturing raising the content of phospholipids and changes in the lecithin-
sphingomyelin ratio (20). 
2. Breast stimulation 
Nipple suction, probably by neural via, during breastfeeding, rises the serum values of 
prolactin, especially in the first weeks after giving birth in direct relation to the lactotroph 
hypertrophy by the estrogenic stimulus of the pregnancy (18-20) 
3. Stress 
Any kind of stress, physical or psychical, can cause hyperprolactinemia, which is normally 
slight, and rarely over 40 ng/ml. 
4. Sexual contact 
There is a dopamine decreasing after orgasm, immediately, the prolactin rises, in men and 
women, acting as a sexual satiation mechanism (21). In men, without any doubt contributes 
to the “turn around and snore” phenomenon. In women, its effects can be delayed. 
Kruger TH et al have demonstrated that sexual intercourse with orgasm induced not only 
the well-established immediate prolactin increasing of 300% but also an additional prolactin 
elevation around noon of the next day. These fluctuations were measured on top of regular 
circadian rhythm (22). 
6. Pathological causes 
Pathological hyperprolactinemia can be caused by: lactotroph hyperplasia, lactotroph cells 
adenoma (prolactinoma) and miscellaneous. 
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1. Lactotroph hyperplasia 
Lactotroph hyperplasia derives, in most cases, from the decrease of the dopamine 
inhibitory tone over the lactotroph cells. Hypothalamic and pituitary stalk lesions can 
cause light or moderated hyperprolactinemia, normally less than 150 ng/ml (18-19, 23). 
The most common cause of hyperprolactinemia are the drugs. Any substance that acts 
over the central nervous system can, potentially, change the prolactin serum levels. 
Generally, the serum prolactin concentration increase a few hours or days after the drug 
administration and it gets normal from 2 to 4 days after its suspension.  
Drugs can be divided in two big groups: drugs that act over the hypothalamus altering 
the dopamine metabolism and the drugs that act directly over the hypophysis. These 
last ones are more powerful and its action mechanism is dopamine antagonist, 
displacing it from its receptor in the lactotroph cell. Examples of these are the 
metoclopramide, sulpiride and domperidone. The Antihypertensives as reserpine and 
methyldopa act in the hypothalamus. Cimetidine and similar substances stimulate the 
receptor H2 and provoke the hyperprolactinemia. 
The hyperprolactine grade depends on the drug, for example, haloperidol can provoke 
rises lower than 20 ng/ml, but the risperidone can raise it over 100 ng/ml (19). 
Estrogens rise the prolactin secretion and explain the higher response of prolactin in 
women in the presence of the different physiological stimulus. 
Besides, up to a 30% of the patients with polycystic ovary syndrome show a light 
hyperprolactinemia, and the treatment with dopaminergic agonists can, in some cases, 
normalize the menstrual cycle. 
The primary hypothyroidism is associated with a slight increase of the prolactin serum 
concentration in a 40% of the patients, but values over 25 ng/ml appear in less of the 
10% (19, 23). 
2. Lactotroph cells adenoma: prolactinoma 
It is the most frequent secretory pituitary tumor and it represents a 60% of the operating 
tumors. The 90% of the prolactinomas are intrasellar microadenomas (<10 nm). 
In women, over 90% are microadenomas, especially between 20 and 40 years old (2, 3). 
In male, the 60% are macroadenomas and it is because the poor symptoms, the delay of 
the medical visit for erectile dysfunction or a higher growth rate (19). 
Prolactinomas are the most common pituitary tumors and they are, normally, benign. 
They are more frequent in women, but they can also appear in men. The symptoms that 
they cause, if the symptoms appear, are related to prolactin excess and so, the milk 
production in non-pregnant women, which is called galactorrhea. 
Prolactinoma, the same as other pituitary neoplasms, comes from a monoclonal expansion 
of a cell that has mutated (18, 19, 23). It is usually sporadic and benign and it is rarely 
malign and metastatic. 
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Sometimes, it takes part of the type one multiple endocrine neoplasms (MEN). It is the only 
pituitary tumor with an effective medical treatment. 
The prolactinoma natural history shows that over 90% of the microadenomas do not grow 
and they do not progress to macroadenomas, that suggest that these have a different 
biological behavior to the microadenomas (19, 24-27), Most of the times the lactotroph 
cells are the only ones affected but up to a 10% can alter, as well, the somatotropes or 
the mamosomatotropes, and a prolactin and growth hormone (GH) co-secretion is 
produced. 
Prolactinoma can lead to: 
- Interruption of the pulsatile secretion of the gonadotropin releasing hormone (GnRH) 
with inhibition of the gonadal steroids production and can provoke infertility and 
hypogonadism. 
- Compression over adjacent structures. 
- Deleterious effects over the organism, specifically the skeleton.  
Prolactin secretion by the prolactinoma is characterized by: 
1. Its efficiency: even small tumors, smaller than 1 cm, can produce significant 
hyperprolactinemia. 
2. Its proportionality: usually, the prolactin serum concentration rises in direct relation to 
the adenoma size: 
- < 1cm is associated with serum prolactin values under 200 ng/ml. 
- Between 1 and 2 cm usually leads to values between 200 and 1000 ng/ml. 
- > 2 cm leads to prolactinemia over 1.000 ng/ml. 
Discrepancies are frequent: 
1. Big tumors with light hyperprolactinemia: they are usually atipic prolactinomas, worse 
differentiated and, so, less sensitive to therapy  with dopaminergic agonists and more 
susceptible to surgical treatment. 
2.  Hook effect: very high levels of prolactin secreted by the macroadenoma saturate the 
assays and lead to an apparently low value (between 20 and 200 ng/ml), which could 
confuse the macroprolactinoma with a non-secretory macroadenoma. It is produced by 
interferences in the enzime inmunoassays for prolactin and it can be settled by serum 
dilution to 1:100, which will show the real prolactin serum values secreted by the tumor 
(19, 28-29). 
7. Miscellaneous 
1.  Decrease of the prolactin clearing: 
a. Chronic renal insufficiency. (CRI) 
The hyperprolactinemia appears in most of the patients with CRI and dialysated. When 
these patients take medication that can alter the hypothalamic regulation of the 
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prolactin, this can take to serum values over 2000 ng/ml. It is produced by a decrease of 
the glomerular filter, although a pituitary primary defect associated to a renal failing 
cannot be dismissed. 
b. Macroprolactinemia.  
In some patients with hyperprolactinemia without a perceptible cause or idiopathic, 
this could be due to an excess of macromolecules of prolactin, known as macroprolactin 
or big prolactin. The macroprolactin is a complex of prolactin joined to an IgG antibody 
with a low bioactivity but with a higher mean life than normal prolactin, of 23 kDa, 
which condition its lower clearing and the consequent accumulation of high serum 
concentrations. 
To distinguish it from other causes, some samples of serum with polyethylene glycol 
should be precipitated (13, 19-20). 
This prolactin variety can be present in over 10% of the patients with 
hyperprolactinemia, and its presence should be suspected in every hyperprolactinemia 
without a defined etiology, with poor or nonexistent symptomatology, despite of the 
high prolactin serum concentrations and with poor or nonexistent response to normal 
therapy with dopaminergic agonists (13,19-20, 28-30).  
This situation can lead to unsuitable diagnosis and treatments in patients with 
hyperprolactinemia, but usually without clinical significance. Every hyperprolactinemia 
assay should consider the possible presence of macroprolactinemia (19, 30). 
When the cause is not found and the imaging tests are negative, the hyperprolactinemia 
is defined as idiopathic. In most of the cases they are small microadenomas. A 10% of 
them will be visible between 2 and 6 years. In other cases it is a transitory and self-
limited disorder that can be solved spontaneously (19,31). 
2. Hyperprolactinemia related to psychotropic drugs 
Prolactin determinations will not be needed in individual under psychotropic treatment, but 
if there is indicative clinical symptoms of hyperprolactinemia. 
However, in a patient with hyperprolactinemia under psychotropic drugs, among others, 
subsequent studies (hormonal and imaging) will be performed only if: 
- There are clinical symptoms derived from hyperprolactinemia. 
- There are prolactin serum concentrations over 6 times the normal value. 
The assessment of the new patient should be done ideally 3 months after the medication 
suppression or, if not possible, the possibility of a substitutive medication that does not 
provoke hyperprolactinemia should be assessed, always under psychiatric control. 
It is normally not recommended the dopaminergic agonists use in a combined 
form to psychotropic or dopaminergic antagonist drugs because of the undesirable effects. 
(19,20). 
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8. Assessment and diagnosis of the hyperprolactinemia 
Because the secretion of the prolactin is pulsatile, it is advisable to determine the serum 
prolactin in, at least, 2 times or more. 
To the most of the clinical laboratories, the normal serum concentration is less than 25 ng/ml 
in women and 20 ng/ml in men. 
(Note: conversion factor: mU/l × 0,0472 =ng/ml; ng/ml × 21,2 = mU/l.) 
The determination should be done, ideally, in a basal situation, under rest conditions and 
after suppression of any medication that can interfere in its quantification. 
The clinical records are determinant to the hyperprolactinemia treatment: 
- The data collection, especially about drugs, must be meticulous. 
- Other non-pituitary causes should be dismissed: pregnancy, thyroid, renal, hepatic and 
adrenal dysfunction. 
- We should investigate the existence of compressive symptomatology like cephalalgia, 
chiasmatic syndrome, liquorrhea and pituitary dysfunction data related to the pituitary 
tumor presence. 
Values of serum prolactin can lead to the diagnosis (figure 6): 
- Serum concentrations slightly raised (20-40 ng/ml) require confirmation before 
cataloguing the hyperprolactinemia state. 
- Prolactin serum values between 20 and 200 ng/ml can appear in iatrogenic or 
extrapituitary hyperprolactinemia. 
- Serum values between 40 and 100 ng/ml appear in secondary and idiopathic causes and 
less frequently in some microprolactinomas. 
- Serum concentrations between 100 and 200 ng/ml, ruled out the pregnancy, are 
characteristic of a prolactinoma. 
- Values over 200 ng/ml appear in macroprolactinomas. 
It is convenient to insist in the importance of differentiate between the big pituitary non-
secretory macroadenomas, that apply compression to the pituitary stalk and can curse with 
prolactin serum values that are not too high, generally lower than 200 ng/ml (pseudo-
prolactinoma) from the real macroprolactinomas, which usually show prolactin serum 
concentrations over 200 ng/ml. 
The first ones are susceptible of surgical treatment, while the prolactinomas are treated, 
most of them, with medical treatment. In a same way, low prolactin serum concentrations 
can coexist with uncovered small tumors in an incidental way, and they can lead to false 
diagnosis of microprolactinoma (19, 33). 
Nevertheless, values between 20 and 200 ng/ml, in presence of a macro-lesion, obliged to 
reassess the samples using a dilution of 1:100 to dismiss the hook effect described previously 
and according to it very high values of serum prolactin saturate the assays and lead to an 
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apparently low value, that could confuse the macroprolatinoma with a non-secretory 
macroadenoma (31). 
 
This image is propriety of our laboratory and created by us. 
Figure 6. Diagnosis of the hyperprolactinemia 
The dynamic tools of suppression or stimulation of prolactin (TRH, L-dopa, etc.) offer 
inconsistent results and should be rejected (19). In the study of the pituitary gland 
functionalism, in the case os a microadenoma, the determination of the basal pituitary 
hormones would be normally enough. 
On the other hand, the presence of a macroadenoma would make advisable a deepest 
anterior hypophysis study. 
9. Protocol of samples extraction to determine the serum prolactin 
Prolactin measurement is subjected to a very careful extraction protocol, because most of the 
errors happen in the pre-analytic stage (between 53-75%) (20, 32). 
Due to some physiological stimulus that rise prolactin levels, it is recommended to use 2-3 
samples obtained at different times to assure that a patient suffers hyperprolactinemia (19-
20). 
Some clinical guides as the “Pituitary Society Guidelines” (35) recommend the 
macroprolactin screening under certain conditions (moderate increase of prolactin levels 
and the patient should not show typical symptoms associated to hyperprolactinemia). Other 
authors recommend the macroprolactin screening performing to all those samples that show 
high prolactin concentrations (19, 20, 36). 
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Our work team has developed a protocol to optimize the samples extraction and the 
monomeric prolactin measurement, when values are above the reference limits (19). This 
procedure has shown to reduce the amount of false hyperprolactinemias if compared to the 
direct puncture technique, because this eliminates the possible increase of prolactin due to 
stress puncture. 
In our protocol (figure 7), patient visit us at 8.00 a.m., following the pre-analitic 
requirements for prolactin measurement (table 2). Then we place a micro-diffusor 
(canalizing the vein, which stays permeable, salinizing the blood vessel puncture). Once it 
has been 60 minutes since the micro-diffuser placement, we will extract the blood sample. 
 
 
This image is propriety of our laboratory and created by us. 
Figure 7. Protocol of extraction samples to determine the serum prolactin 
 
 Being awake 2 hours before extraction and without making any physical effort. 
 Avoid high-protein diet from the day before the extraction 
 Avoid high-fat diet from the day before the extraction. 
 Avoid breast stimulation from the day before the extraction. 
 Be 8-10 hours of fasting prior to extraction. 
 Do not take medications that may increase or decrease prolactin. 
 Be relaxed and rested for at least 30 min before extraction. 
 Do not be under stress.
Table 2. Conditions for the extraction of prolactin 
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The monomeric fraction determination was performed when we found high prolactin levels 
after 60 minutes, then we perform the macroprolactin precipitation through PEG 6000 
(20, 36) 
Polyethylene glycol was mixed in equal parts with the patient serum, then it was stirred and 
centrifuged. Prolactin was measured in the supernatant (monomeric prolactin). 
We show in our report the prolactin measure at 60 minutes, the percentage of recuperation 
after precipitation with PEG 6000 and the monomeric prolactin (we add in a note this is the 
fraction that has biological activity). 
10. Imaging techniques 
Neuro-imaging studies must be performed with any hyperprolactinemia degree that cannot 
be explained with the purpose of dismiss the hypothalamic-pituitary diseade. 
The Magnetic resonance imaging (MRI) with gadolinium gives the most precise anatomical 
details, and let us measure the tumor size and its relation to the optical chiasma and the 
cavernosus sinus, that is why this is, nowadays, the best imaging technique (19, 32). If MRI 
is normal, after excluding other hyperprolactinemia causes, we should talk about idiopathic 
hyperprolactinemia. 
Computed tomography with intravenous contrast is less efficient than MRI in small 
adenomas diagnosis and the definition of big tumors, but it can be used if MRI cannot be 
used or if it is contraindicated. The rest of the image techniques that are more usual like X-
Rays and isotope techniques are not recommended. (37). 
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